C07K 14/5255
Lymphotoxin [lt]
Official title: {Lymphotoxin [LT]}
C07K14/5255 (Lymphotoxin [lt]) appears on 36 US grants and 34 published applications in this corpus.
Search patents in C07K- Granted patents
- 36
- Published applications
- 34
- Assignees
- 25
- Inventors
- 76
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 5 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 5 |
| 2003 | 2 | 4 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 6 | 1 |
| 2007 | 0 | 3 |
| 2008 | 0 | 0 |
| 2009 | 3 | 2 |
| 2010 | 0 | 2 |
| 2011 | 1 | 2 |
| 2012 | 1 | 2 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 2 |
| 2024 | 1 | 1 |
| 2025 | 0 | 3 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody3 Mar 2026US 12,565,530 B2Hoffmann-La Roche Inc.
- ATP-dependent agonists of immune cells function as anticancer agents31 Dec 2024US 12,180,297 B2Crosslink Therapeutics Inc.
- Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing7 Sep 2021US 11,111,284 B2The General Hospital Corporation
- Antibody-light fusion products for cancer therapeutics18 Apr 2017US 9,623,116 B2The University of Chicago
- Antibody-light fusion products for cancer therapeutics23 Jun 2015US 9,061,073 B2The University of Chicago
- Fusion protein comprising light protein and anti-fap antibody and uses thereof4 Dec 2025US 2025/0368754 A1Kanaph Therapeutics Inc.
- Multivalent display on enveloped particles with human oligomerization domains18 Sep 2025US 2025/0288662 A1Achelois Biopharma, Inc.
- ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents19 Jun 2025US 2025/0197521 A1Crosslink Therapeutics Inc.
- ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents1 Aug 2024US 2024/0254254 A1Crosslink Therapeutics Inc.
- Combination therapy with targeted 4-1bb (cd137) agonists9 Nov 2023US 2023/0357397 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
- Tumor necrosis factor antagonists and their use250US 5,795,967 AGenentech, Inc. · 1998
- Tumor necrosis factor antagonists and their use137US 5,672,347 AGenentech, Inc. · 1997
- Vitro protein synthesis using glycolytic intermediates as an energy source122US 6,337,191 B12002
- Recombinant antibody cytokine fusion proteins116US 5,650,150 A1997
- In vitro synthesis of polypeptides by optimizing amino acid metabolism70US 6,994,986 B2The Board of Trustees of the Leland Stanford University · 2006